Andres Deik
University of Pennsylvania
40 Papers
84 Citations
Andres Deik is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Medicine & Dystonia. The author has an hindex of 12, co-authored 33 publications. Previous affiliations of Andres Deik include Icahn School of Medicine at Mount Sinai & Beth Israel Deaconess Medical Center.
Chat about Author
Papers
The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease
Ziv Gan-Or,Laurie J. Ozelius,Anat Bar-Shira,Rachel Saunders-Pullman,Anat Mirelman,Ruth Kornreich,Mali Gana-Weisz,Deborah Raymond,Liron Rozenkrantz,Andres Deik,Tanya Gurevich,Susan J. Gross,Nicole Schreiber-Agus,Nir Giladi,Susan B. Bressman,Avi Orr-Urtreger +15 more
TL;DR: The identification of the SMPD1 p.L302P mutation as a strong risk factor for PD may further elucidate PD pathogenesis and the role of lysosomal pathways in disease development.
A new in vitro model of the glial scar inhibits axon growth
Ina B. Wanner,Andres Deik,Miguel Torres,Andrew Rosendahl,Joseph T. Neary,Vance Lemmon,John L. Bixby +6 more
TL;DR: The in vitro model of the scar showed relevant aspects of scar formation and produced widespread inhibition of axonal regeneration; it should be useful both for examining mechanisms underlyingScar formation and to assess various treatments for their potential to improve regeneration after CNS injury.
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
Roy N. Alcalay,Anat Mirelman,Rachel Saunders-Pullman,Ming X. Tang,Helen Mejia Santana,Deborah Raymond,Ernest Roos,Martha Orbe-Reilly,Tanya Gurevich,Anat Bar Shira,Mali Gana Weisz,Kira Yasinovsky,Maayan Zalis,Avner Thaler,Andres Deik,Matthew J. Barrett,Jose Cabassa,Mark Groves,Ann L. Hunt,Naomi Lubarr,Marta San Luciano,Joan Miravite,Christina Palmese,Rivka Sachdev,Harini Sarva,Lawrence Severt,Vicki Shanker,Matthew Swan,Jeannie Soto-Valencia,Brooke Johannes,Roberto A. Ortega,Stanley Fahn,Lucien J. Cote,Cheryl Waters,Pietro Mazzoni,Blair Ford,Elan D. Louis,Oren A. Levy,Llency Rosado,Diana Ruiz,Tsvyatko Dorovski,Michael W. Pauciulo,William C. Nichols,Avi Orr-Urtreger,Avi Orr-Urtreger,Laurie J. Ozelius,Lorraine N. Clark,Nir Giladi,Susan Bressman,Karen Marder +49 more
TL;DR: PD in AJ LRRK2 G2019S mutation carriers is similar to idiopathic PD but is characterized by more frequent lower extremity involvement at onset and PIGD without the associated cognitive impairment.
149
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial
Michael A. Schwarzschild,Alberto Ascherio,Cindy Casaceli,Gary C. Curhan,Rebecca Fitzgerald,Cornelia Kamp,Codrin Lungu,Eric A. Macklin,Kenneth Marek,Dariush Mozaffarian,David Oakes,Alice Rudolph,Ira Shoulson,Aleksandar Videnovic,Burton L. Scott,Lisa Gauger,Jason Aldred,Melissa Bixby,Jill Ciccarello,Steven A. Gunzler,Claire Henchcliffe,Claire Henchcliffe,Matthew Brodsky,Kellie Keith,Robert A. Hauser,Christopher G. Goetz,Mark S. LeDoux,Vanessa K. Hinson,Rajeev Kumar,Alberto J. Espay,Joohi Jimenez-Shahed,Christine Hunter,Chadwick W. Christine,Aaron Daley,Maureen A. Leehey,J. Antonelle de Marcaida,Joseph H. Friedman,Albert Y. Hung,Grace Bwala,Irene Litvan,David Simon,Tanya Simuni,Cynthia Poon,Mya C. Schiess,Kelvin L. Chou,Ariane Park,Danish Bhatti,Carolyn Peterson,Susan R. Criswell,Liana S. Rosenthal,Jennifer Durphy,Holly A. Shill,Shyamal H. Mehta,Anwar Ahmed,Andres Deik,John Y. Fang,Natividad Stover,Lin Zhang,Richard B. Dewey,Ashley Gerald,James T. Boyd,Emily Houston,Valerie Suski,Sherri Mosovsky,Leslie J. Cloud,Binit B. Shah,Marie Saint-Hilaire,Raymond C. James,Sarah Elizabeth Zauber,Stephen G. Reich,David Shprecher,Rajesh Pahwa,April Langhammer,Kathrin LaFaver,Peter A LeWitt,Patricia Kaminski,John L. Goudreau,Doozie Russell,David J. Houghton,Ashley Laroche,Karen Thomas,Martha McGraw,Zoltan Mari,Carmen Serrano,Karen Blindauer,Marcie Rabin,Roger Kurlan,John C. Morgan,Michael Soileau,Melissa Ainslie,Ivan Bodis-Wollner,Ruth B. Schneider,Cheryl Waters,Amber Servi Ratel,Christopher A. Beck,Patrick Bolger,Katherine F. Callahan,Grace F. Crotty,David Klements,Melissa Kostrzebski,Gearoid M. McMahon,Lindsay Pothier,Sushrut S. Waikar,Anthony E. Lang,Anthony E. Lang,Tiago A. Mestre +105 more
TL;DR: A randomized, double-blind, placebo-controlled, phase 3 trial of oral inosine treatment in early Parkinson disease was conducted in this article, and the results showed no significant difference in the rate of clinical disease progression.
109
Clinical Spectrum of Stiff Person Syndrome: A Review of Recent Reports
Harini Sarva,Andres Deik,Aman Ullah,William Severt +3 more
- 04 Mar 2016
TL;DR: Grouping SPS-spectrum cases by pathophysiology provided insights into work-up, treatment, and prognosis, and ruled out malignancy and autoimmunity is appropriate for suspected SPCS cases.